SCREENING FOR THROMBOPHILIA AND PREGNANCY COMPLICATIONS
|
08:30-10:30
|
PLENARY SESSION I: Screening for thrombophilia and pregnancy complications
|
|
Chairpersons
|
S. Middeldorp, Netherlands
A. Lubetsky, Israel
|
| 08:30 |
Debate: Screening for thrombophilia
Always: A. Lubetzky, Israel
Never: I. Martinelli, Italy
Discussion
|
| 09:20 |
Debate: Role of thrombophilia in pregnancy complications
Major: B. Brenner, Israel
Minor: S. Middeldorp, Netherlands
Discussion
|
| 10:10 |
Oral Presentation:
VEGFA GENE PROMOTER POLYMORPHISMS AND RISK OF VENOUS THROMBOEMBOLISM IN AMBULATORY CANCER PATIENTS
P. Ferroni, Italy
|
| 10:30 |
Coffee Break and poster viewing |
HEPARIN, WARFARIN AND NOVEL ANTICOAGULANTS
| 11:00-13:00 |
PARALLEL SESSION II: Heparin, Warfarin and novel anticoagulants
|
| Chairpersons |
I. Birschmann, Germany
B. Brenner, Israel
|
| 11:00 |
State of the Art: NOACs for the treatment and prevention of VTE
A. Lubetsky, Israel |
| 11:30 |
Debate: NOACs in cardiology
Advantages: E. Lev, Israel
Limitations: B. Brenner, Israel
Discussion
|
| 12:20 |
Laboratory evaluation of DOACs - dos and dont's
I. Birschmann, Germany
|
| 12:40 |
Oral Presentation:
COAGULATION RESONANCE AMPLITUDE (CORA) TECHNOLOGY PROVIDES A NOVEL VISCOELASTIC ASSESSMENT OF SIMULTANEOUS COAGULATION COMPONENT ANALYSIS
J. Kashuk, Israel
|
| 13:00 |
Lunch break and poster viewing
|
ANTIPLATELET THERAPY & MONITORING
| 16:30-18:30 |
PARALLEL SESSION V: Antiplatelet therapy and monitoring |
| Chairpersons |
A. Michelson, USA
M. Cattaneo, Italy
|
| 16:30 |
Debate: Monitoring anti platelet therapy?
Helpful: R. Storey, UK
Not helpful: M. Cattaneo, Italy
Discussion |
| 17:20 |
Debate: New antiplatelet agents
Advantages: E. Lev, Israel
Limitations: A. Michelson, USA
Discussion |
| 18:10 |
Oral Presentation:
AMYLOID PEPTIDE-DEPENDENT ACTIVATION OF HUMAN PLATELETS: ESSENTIAL ROLE FOR CA2+ AND ADP
G. Pula, UK
|
| 18:20 |
Oral Presentation:
THE NOVEL NOX INHIBITOR 2-ACETYLPHENOTHIAZINE IMPAIRS COLLAGEN-DEPENDENT THROMBUS FORMATION IN A GPVI-DEPENDENT MANNER
G. Pula, UK
|
SATURDAY, NOVEMBER 1, 2014
PHARMACOGENOMICS; THROMBOLYTIC THERAPY
| 10:30-12:30 |
PLENARY SESSION VII: Pharmacogenomics; Thrombolytic therapy
|
| Chairpersons |
D. Varon, Israel
Y. Caraco, Israel
|
| 10:30 |
State of the Art:
Pharmacogenomics in thrombosis and hemostasis
Y. Caraco, Israel |
| 11:10 |
State of the Art:
Catheter guided thrombolysis in VTE
A.I. Bloom, Israel
Discussion
|
| 11:50 |
Oral Presentation:
EXTRACELLULAR FIBRINOGEN BINDING PROTEIN INHIBITS THROMBUS FORMATION BY INTERACTING WITH PLATELETS IN A FIBRINOGEN-DEPENDENT MANNER: UNEXPECTED RESULTS AND NOVEL HYPOTHESES
G. Pula, UK
|
| 12:10 |
Oral Presentation:
CATHETER DIRECTED THROMBOLYSIS ALONG WITH MECHANICAL THROMBOASPIRATION IN THE MANAGEMENT OF PROXIMAL LOWER LIMB DEEP VENOUS THROMBOSIS: A PROSPECTIVE STUDY WITH 6-MONTH FOLLOW-UP
S. Patra, India
|
| 12:30 |
Lunch Break and poster viewing |
PRIMARY PREVENTION OF VENOUS THROMBOSIS AND CORONARY ARTERY DISEASE
| 16:00-17:45 |
PARALLEL SESSION X: Primary prevention of venous thrombosis and coronary artery disease
|
| Chairpersons |
C. Patrono, Italy
Y. Caraco, Israel
|
| 16:00 |
State of the Art: Extended venous thromboembolism prophylaxis in medically ill patients
Y. Caraco, Israel
|
| 16:40 |
Debate: Primary prevention of coronary artery disease by aspirin
No: R. Storey, UK
Yes, because of other potential benefits: C. Patrono, Italy
Discussion
|
